Compositions for affecting weight loss comprising an opioid antagonist and bupropion

European Patent Office Patent

PATENT NO 2316456
APP PUB NO EP-2316456-A1
SERIAL NO

10185782

Stats

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ±-MSH activity.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • Owner owned or assignment not recorded

International Classification(s)

Inventor(s)

  • No Inventor to display

Cited Art Landscape

Load Citation